Cost of treatment of schizophrenia in six European countries
dc.contributor.author | Salize, HJ | en_US |
dc.contributor.author | McCabe, R | en_US |
dc.contributor.author | Bullenkamp, J | en_US |
dc.contributor.author | Hansson, L | en_US |
dc.contributor.author | Lauber, C | en_US |
dc.contributor.author | Martinez-Leal, R | en_US |
dc.contributor.author | Reinhard, I | en_US |
dc.contributor.author | Rossler, W | en_US |
dc.contributor.author | Svensson, B | en_US |
dc.contributor.author | Torres-Gonzalez, F | en_US |
dc.contributor.author | van den Brink, R | en_US |
dc.contributor.author | Wiersma, D | en_US |
dc.contributor.author | Priebe, S | en_US |
dc.date.accessioned | 2011-01-18T12:05:28Z | |
dc.date.available | 2009-03-21 | en_US |
dc.date.issued | 2009-06 | en_US |
dc.identifier.issn | 0920-9964 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/319 | |
dc.format.extent | 70 - 77 | en_US |
dc.relation.ispartof | SCHIZOPHR RES | en_US |
dc.subject | Schizophrenia | en_US |
dc.subject | Community care | en_US |
dc.subject | Service utilization | en_US |
dc.subject | Cost of care | en_US |
dc.subject | Psychopharmacologic costs | en_US |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | en_US |
dc.subject | LATEST ANTIPSYCHOTIC-DRUGS | en_US |
dc.subject | MENTAL-HEALTH-SERVICES | en_US |
dc.subject | QUALITY-OF-LIFE | en_US |
dc.subject | SPAIN | en_US |
dc.subject | CARE | en_US |
dc.subject | 2ND-GENERATION | en_US |
dc.subject | CUTLASS-1 | en_US |
dc.subject | COMMUNITY | en_US |
dc.subject | UTILITY | en_US |
dc.title | Cost of treatment of schizophrenia in six European countries | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1016/j.schres.2009.03.027 | en_US |
pubs.issue | 1-3 | en_US |
pubs.notes | Not known | en_US |
pubs.volume | 111 | en_US |
Files in this item
This item appears in the following Collection(s)
-
Centre for Psychiatry [791]